TuHURA Biosciences IncHURA
Price$2.10

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Mar 2026
Net Income -$30.1MTTM through 30 Jun 2026
Free Cash Flow -$29.9MTTM through 30 Jun 2026

Margins

Current

Returns

-133.6%ROE
-104.3%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio1.15x
Net Debt-$6.3Mnet cash position
Cash & Equivalents$996K

Quality Metrics

Altman Z-Score-4.23
Piotroski F-Score1 / 9
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'11'12'23'24'25
FY2025: $0
Diluted EPS-$0.54TTM
'14'15'23'24'25
FY2025: $-0.63

Dividend

No dividend

Capital Allocation

R&D Spend$22.9M

Segment Performance

SegmentRevenueYoYOutlook
Immuno-oncology Therapeutics$0
View details

Top-line data for the Phase 3 IFx-2.0 trial is anticipated in the second half of 2027. Phase 1b/2 trial initiation for TBS-2025 is planned for the second half of 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.